RESUMO
In this study 15 consecutive melanoma patients were treated with two courses of bolus recombinant interleukin 2 (rIL2) and rIL2 plus in vitro-generated lymphokine-activated killers (LAK), respectively. The immunological monitoring performed after 4 days of rIL2 or rIL2 plus LAK, indicate that the in vivo peripheral blood lymphocyte (PBL), activation (spontaneous proliferation, tumor cytotoxicity, number of DR+ PBL, obtained after the second cycle of rIL2 plus LAK is significantly higher than after the first cycle of rIL2 alone. During the 5-day interval between the two courses, PBL activation returns to baseline levels and no evidence for increased sensitivity of PBL to rIL2 is present. To further confirm this, two additional patients were studied, in whom rIL2 was administered by continuous i.v. infusion. In these two patients the in vitro versus in vivo PBL activation could be directly and simultaneously compared by using in vitro the same concentration of rIL2 reached and maintained in the patients' sera. The PBL activation induced in vivo by a cycle of rIL2 alone was significantly less (about 10 times) than that obtained in vitro with a comparable rIL2 concentration. Thus, the infusion of in vitro highly activated PBL could explain the increased in vivo lymphocyte activation of the second cycle of rIL2 plus LAK over the first cycle of rIL2 alone.
Assuntos
Interleucina-2/uso terapêutico , Células Matadoras Naturais/imunologia , Ativação Linfocitária/efeitos dos fármacos , Linfócitos/imunologia , Melanoma/terapia , Linhagem Celular , Citotoxicidade Imunológica/efeitos dos fármacos , Humanos , Imunoterapia , Interleucina-2/farmacologia , Células Matadoras Naturais/efeitos dos fármacos , Linfócitos/efeitos dos fármacos , Linfocinas/farmacologia , Melanoma/imunologia , Proteínas Recombinantes/farmacologia , Proteínas Recombinantes/uso terapêuticoRESUMO
Circulating haematopoietic progenitors from 36 cancer patients were collected by continuous-flow leukapheresis during the phase of rapid haematopoietic recovery after pancytopenia induced by high-dose cyclophosphamide and then cryopreserved for autologous transplantation. 20 of the patients also received intravenous infusion of recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF) for 7, 10 or 14 days after cyclophosphamide. 106 leukapheresis procedures were done for 2-5 consecutive days. Leukapheresis was started significantly earlier in patients receiving rhGM-CSF. In these patients, yields of peripheral blood elements (leucocytes, mononuclear cells, haematopoietic progenitors and platelets) were significantly higher than in controls treated with cyclophosphamide only. In particular, the mean number of granulocyte-monocyte colony-forming cells was 43.88 X 10(4) vs. 6.16 X 10(4) per kg patient body weight per leukapheresis. Side-effects of leukapheresis were limited to central venous catheter occlusion and fever in 4% and 2% of all procedures, respectively.
Assuntos
Fatores Estimuladores de Colônias/uso terapêutico , Ciclofosfamida/uso terapêutico , Substâncias de Crescimento/uso terapêutico , Transplante de Células-Tronco Hematopoéticas , Neoplasias/terapia , Adulto , Contagem de Células Sanguíneas , Ensaio de Unidades Formadoras de Colônias , Feminino , Fator Estimulador de Colônias de Granulócitos e Macrófagos , Humanos , Leucaférese/efeitos adversos , Masculino , Pessoa de Meia-Idade , Proteínas Recombinantes/uso terapêutico , Fatores de TempoRESUMO
Previous work has shown that infusion of autologous helper-enriched, alloactivated lymphocytes in melanoma patients may induce, in addition to other mild signs of toxicity, a transient but sharp elevation of blood pressure. To avoid such a disturbing symptom, the in vitro protocol of peripheral blood lymphocyte activation has been modified. In the present study we show that such a modification has led to a lower toxicity of autologous lymphocyte infusion in 4 melanoma patients; in particular, hypertension was no longer observed. In addition, an immunologic monitoring was carried out in these patients. In 1 of 4 patients the treatment enhanced the in vitro cytotoxic activity of peripheral blood lymphocytes against autologous tumor cells. Other parameters such as NK activity and T4/T8 ratio did not show significant trends. The possible implications of these findings for clinical trials of adoptive immunotherapy with lymphocytes are discussed.
Assuntos
Imunoterapia/métodos , Linfócitos/imunologia , Melanoma/terapia , Adolescente , Transfusão de Sangue Autóloga , Citotoxicidade Imunológica , Feminino , Humanos , Interleucina-1/biossíntese , Interleucina-2/biossíntese , Ativação Linfocitária , Masculino , Melanoma/imunologia , Pessoa de Meia-IdadeRESUMO
A new procedure for activation of peripheral blood lymphocytes (PBL) with recombinant interleukin 2 (rIL2) is described. PBL obtained by leukapheresis were subjected to NH4Cl (ACK) treatment to clear erythrocyte contamination; Ficoll separation was not performed. PBL were subsequently seeded in 10-floor multitrays (Cell FactoryTM, CF), gasified and incubated at 37 degrees C for 3-4 days in a humidified 5% CO2 atmosphere. This procedure achieved an activation (evaluated as cytotoxicity and proliferation) comparable with that obtained by culturing PBL in small flasks. Optimal activation of PBL was achieved in CF even in the presence of granulocyte contamination of up to 40%. It was also possible to freeze, thaw and recover most of the frozen cells and their cytotoxic activity. With this procedure therefore large quantities of lymphokine activated killer cells (LAK) can be easily produced to be used in adoptive immunotherapy trials.
Assuntos
Imunização Passiva , Interleucina-2/farmacologia , Células Matadoras Naturais/imunologia , Ativação Linfocitária , Neoplasias/terapia , Preservação de Sangue/métodos , Separação Celular , Congelamento , Humanos , Proteínas Recombinantes/farmacologiaRESUMO
From January 1987 to February 1988, 15 stage IV melanoma patients were treated with two courses of bolus injection of rIL-2 plus LAK cell infusions at the National Cancer Institute of Milan. The original treatment regimen included a first course of rIL-2 administration (400 micrograms/m2 bolus injection 3 times a day [TID] for 4 days) and a second course of rIL-2 administration (800 micrograms/m2 bolus injection TID for 7 days) separated by 4 consecutive daily leukaphereses. Autologous lymphokine activated killer (LAK) cells were reinfused into each patient on three occasions during the second period of rIL-2 administration. Due to the appearance of grade III-IV neurological, hepatic and cardiopulmonary toxicity, 7 patients discontinued dosing before the end of treatment, one patient desired to be withdrawn and one patient died from rapidly progressive disease, although complications of rIL-2 administration may have contributed to her death. Only 6 patients completed the schedule without evidence of major intolerance, even though the planned dose during the second course of rIL-2 was reduced to 400 micrograms/m2. The complete duration of treatment ranged from 11 to 19 days. The total dose of rIL-2 injected ranged from 12.6 to 30.4 mg. The number of infused LAK cells ranged from 15.5 x 10(9) to 60 x 10(9)/patient. Two of the 14 evaluable patients showed a minor anti-tumor response. In 5 patients new metastases in other sites were documented from 2 to 5 months after completion of dosing. No apparent association was found between progression of the disease (or the appearance of new metastases) and the total dose of rIL-2 injected, the number of LAK cells administered or the number of days of treatment. By December 1988, all patients had died of their disease in a period ranging from 3 to 14 months from the last injection of rIL-2. The lack of significant clinical responses in this study and the high toxicity of this treatment lead us to conclude that at least as far as melanoma patients are concerned, adoptive immunotherapy with rIL-2 plus LAK cells (as described here) is not a justifiable treatment option unless new evidence presents itself.
Assuntos
Transfusão de Sangue Autóloga , Interleucina-2/uso terapêutico , Células Matadoras Naturais/transplante , Melanoma/terapia , Neoplasias Cutâneas/terapia , Adulto , Transfusão de Sangue Autóloga/efeitos adversos , Avaliação de Medicamentos , Feminino , Testes de Função Cardíaca , Humanos , Imunização Passiva/efeitos adversos , Interleucina-2/efeitos adversos , Interleucina-2/farmacologia , Células Matadoras Naturais/efeitos dos fármacos , Masculino , Melanoma/sangue , Melanoma/patologia , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Proteínas Recombinantes/uso terapêutico , Testes de Função Respiratória , Neoplasias Cutâneas/sangue , Neoplasias Cutâneas/patologiaRESUMO
The authors summarise their experience with the new "early granulocyte transfusion" scheme obtained in cancer patients. The data, based on three trials, clearly point out )1 the importance of early granulocyte transfusion as compared to the traditional one; 2) the efficacy of early granulocyte transfusion in pediatric age and among adult patients in those with good regenerating hemopoietic system.
Assuntos
Transfusão de Sangue , Granulócitos/transplante , Neoplasias/terapia , Doença Aguda , Adolescente , Adulto , Criança , Feminino , Humanos , Controle de Infecções , Leucemia/terapia , Masculino , Fatores de TempoRESUMO
Starting from mucosal cells, isolated from rat small intestine, subcellular fractionation was carried out. Four fractions were prepared and characterized by marker enzymes and electron microscopic examination: nuclei plus microvilli, mitochondria, microsomes and supernatant. Thiamine-pyrophosphokinase activity was localized mainly in the supernatant fraction, with minor amount in mitchondria and microsomes. On the contrary thiamine-pyrophosphatase activity was present only in the particulate fractions (especially in microsomes), being completely absent from the supernatant.
Assuntos
Mucosa Intestinal/enzimologia , Fosfotransferases/metabolismo , Pirofosfatases/metabolismo , Tiamina Pirofosfatase/metabolismo , Animais , Mucosa Intestinal/citologia , Masculino , Ratos , Frações Subcelulares/enzimologiaAssuntos
Acetilcolina/fisiologia , AMP Cíclico/farmacologia , Comportamento de Ingestão de Líquido/efeitos dos fármacos , Comportamento Alimentar/efeitos dos fármacos , Hipotálamo/efeitos dos fármacos , Sistema Nervoso Parassimpático/fisiologia , Animais , Atropina/farmacologia , Carbacol/farmacologia , Hemicolínio 3/farmacologia , Hipotálamo/metabolismo , Hipotálamo/fisiologia , Fisostigmina/farmacologia , Ratos , Transmissão SinápticaAssuntos
Enzimas/sangue , Lisossomos/enzimologia , Acetilglucosaminidase/sangue , Adulto , Plaquetas/enzimologia , Preservação de Sangue , Glucuronidase/sangue , Humanos , Concentração de Íons de Hidrogênio , Leucócitos/enzimologia , Masculino , Manosidases/sangue , Pessoa de Meia-Idade , Manejo de Espécimes , Espectrometria de Fluorescência , alfa-Galactosidase/sangue , alfa-L-Fucosidase/sangue , alfa-Manosidase , beta-Galactosidase/sangueRESUMO
BACKGROUND AND OBJECTIVES: Extracorporeal circuits made of artificial substances may induce blood cells and humoral activation. Negatively charged surfaces may activate Factor XII and the prekallikrein-kinin cascade, resulting in bradykinin (BK) production. BK has been considered to be involved in severe hypotensive reactions occurring during therapeutic apheresis in patients taking angiotensin-converting enzyme (ACE) inhibitors or in those receiving platelet transfusion. In this study we investigated BK production during donor plasmapheresis procedures. PATIENTS AND METHODS: Eighteen volunteer donors entered the study protocol. Nine of them were taking ACE inhibitors. Their blood pressure (BP) was monitored both pre- and post-apheresis, and BK determination was carried out using a competitive enzyme immunoassay (EIA), in plasma samples collected both during and at completion of the procedure. In addition, a limited number of thawed plasma units were checked for BK. RESULTS: No side-effects were observed during the procedures. However, donors taking ACE inhibitors showed a higher variation of their systolic BP compared to those who were not taking ACE inhibitors, while diastolic BP percentage variations did not differ significantly between the two groups. The BK concentration was considerably higher in donors taking ACE inhibitors: 183 +/- 26 versus 82 +/- 6 ng/ml (P < 0.0001) after the first collection cycle and 142 +/- 20 versus 65 +/- 11 ng/ml (P < 0.0001) in the final samples. BK was also detected, at a lower concentration (15 ng/ml), in one out of four thawed plasma units obtained from donors taking ACE inhibitors and at 1 ng/ml in one out of two thawed plasma units from the control group. CONCLUSION: Donors taking ACE inhibitors and undergoing plasmapheresis showed higher levels of BK compared to the control group. Furthermore, the detection of BK in plasma units after a freeze-thaw procedure might explain the sudden hypotensive reaction occurring during therapeutic plasma exchange when plasmapheresis units are adopted as substitution fluids. Further investigations are needed to assess the real clinical importance of the presence of BK in plasma units.
Assuntos
Doadores de Sangue , Bradicinina/biossíntese , Bradicinina/sangue , Plasmaferese/efeitos adversos , Adulto , Inibidores da Enzima Conversora de Angiotensina/administração & dosagem , Inibidores da Enzima Conversora de Angiotensina/farmacologia , Pressão Sanguínea/efeitos dos fármacos , Bradicinina/efeitos dos fármacos , Segurança de Equipamentos , Humanos , Pessoa de Meia-Idade , Plasmaferese/instrumentaçãoRESUMO
BACKGROUND: The importance of transfusing WBC-reduced blood components is widely recognized, as it reduces the risk of alloimmunization and transfusion-transmitted CMV infections. The latest generation of cell separators allows the collection of WBC-reduced apheresis platelet concentrates (APCs). MATERIALS AND METHODS: Consecutive APCs (n = 232) were retrospectively evaluated: 163 collected with the Spectra LRS [leukocyte-reduction system] Version 5.1 (Group A) and 69 with the LRS Turbo Version 7.0 (Group B) (both: COBE BCT). Donor peripheral blood count, procedure data, platelet yield, collection efficiency (CE), and residual WBC count in APCs were recorded. RESULTS: The platelet yield was higher in Group B than in Group A: 5.5 +/- 1.4 versus 4.4 +/- 1.1, p<0.0001; residual WBCs were <5 x 10(6) in 99.4 percent of Group A APCs and in 97.1 percent of Group B APCs. CE was higher in Group B than in Group A: 51.4 +/- 8.7 versus 43.6 +/- 6.3, p<0.0001. Moreover, a correlation between predonation platelet count and platelet yield was observed in both groups. A double product (platelet yield >6.0 x 10(11)) was obtained in 28.9 percent of Group B APCs and in 9.2 percent of Group A APCs. CONCLUSIONS: The Spectra LRS Turbo version 7.0 release showed a better CE and resulted in a higher platelet harvest than did the LRS version 5.1. High predonation platelet counts allow a higher platelet yield.
Assuntos
Transfusão de Plaquetas , Plaquetoferese/instrumentação , Contagem de Células Sanguíneas , Humanos , Estudos RetrospectivosRESUMO
Twenty-seven cancer patients underwent peripheral blood stem cell apheresis during hematopoietic regeneration following induction high-dose cyclophosphamide (7 g/sqm; HD-CTX). Among these patients, eleven were also treated with granulocyte-macrophage colony stimulating factor (rhGM-CSF) for 14 days after HD-CTX. We describe technique, peripheral blood cell yields and side effects of 76 leukaphereses performed using a continuous-flow blood cell separator COBE 2997. Leukaphereses, carried out through 2-5 consecutive days per patient, were started significantly earlier in rhGM-CSF treated patients. In comparison to patients receiving HD-CTX only, administration of rhGM-CSF resulted in a significantly higher yield per leukapheresis of mononuclear cells and granulocyte-macrophage colony forming units (CFU-GM) (two-fold and eight-fold, respectively). Procedures were completed and well tolerated in all cases. Minor side effects were unfrequent. Our results suggest that rhGM-CSF accelerates hematopoietic recovery after HD-CTX and facilitates large-scale collection of peripheral blood stem cells utilizable for autologous transplantation.
Assuntos
Transplante de Medula Óssea/métodos , Fatores Estimuladores de Colônias/farmacologia , Substâncias de Crescimento/farmacologia , Células-Tronco Hematopoéticas/efeitos dos fármacos , Leucaférese/métodos , Feminino , Fator Estimulador de Colônias de Granulócitos e Macrófagos , Humanos , Proteínas Recombinantes/farmacologia , Manejo de Espécimes/métodosRESUMO
Labeled and unlabeled (endogenous) free and phosphorylated thiamine were measured in isolated everted rings of rat jejunum in vitro during short incubation periods (1-10min). Shortly after the addition of thiamine-14C to the incubation medium, the intracellular specific activity of the free form was higher than the specific activity of the phosphorylated fraction. In the course of time this difference diminished and finally the two specific activities became equal. The conclusion was reached that free thiamine is the likely precursor of intracellular phosphorylated thiamine. Moreover evidence is presented which indicates that free thiamine entered actively into intestinal epithelial cells. Since free thiamine was modified into phosphorylated form inside the cells, its movement against the endocellular concentration gradient was noticeably favoured.
Assuntos
Jejuno/metabolismo , Fosfatos/metabolismo , Tiamina/metabolismo , Animais , Transporte Biológico Ativo , Radioisótopos de Carbono , Absorção Intestinal , Mucosa Intestinal/metabolismo , Masculino , Ratos , Fatores de TempoRESUMO
The conditions of a linear assay for 4-methylumbelliferyl-alpha-D-N-acetyl-neuraminic acid (4-MU-NeuAc) sialidase activity in human lymphocytes, granulocytes, platelets and red cells plasma membranes have been determined. Lymphocytes and granulocytes have the same pH curve with two maximums at pH 4.0 and 4.8; however lymphocytes show a higher specific activity and a higher Km value. Sialidase activity detected in red cells plasma membranes has again a double-peak pH curve with maximums at pH 4.2 and pH 4.6, and specific activity levels less than one/30 compared to the other blood cells preparations. Platelets have a sialidase activity of the same magnitude as granulocytes, with an optimum pH at 4.2.
Assuntos
Plaquetas/enzimologia , Membrana Eritrocítica/enzimologia , Granulócitos/enzimologia , Himecromona/metabolismo , Linfócitos/enzimologia , Neuraminidase/sangue , Umbeliferonas/metabolismo , Membrana Celular/enzimologia , Humanos , Concentração de Íons de Hidrogênio , Himecromona/análogos & derivados , CinéticaRESUMO
In recent years peripheral blood stem cell (PBSC) collection for allogeneic or autologous transplantation has experienced an increased use in the onco-hematological setting. The latest generation cell separators allow a satisfactory and safe PBSC collection. Nevertheless, as in all therapeutic apheresis procedures, patients may experience procedure-related side-effects, mainly vasovagal reactions or symptoms related to hypocalcemia and/or hypomagnesemia. We investigated electrolyte changes in 18 patients, with a median age of 46 years (range 7-62), undergoing PBSC collection from January to April 1998. A significant decrease in total calcium in the final sample (9.65 +/- 0.7 mg/dL) with respect to the basal one (9.2 +/- 0.6 mg/dL, P < 0.05) was observed; also ionized calcium decreased markedly from the first sample drawn at +30 minutes: 1.22 +/- 0.14 vs. 1.03 +/- 0.15 mmol/L (P < 0.05), and a highly significant difference emerged when basal value were compared to the final value: 1.22 +/- 0.14 vs. 0.94 +/- 0.13 mmol/L (P < 0.0001). Similar findings affected potassium concentration: 4.1 +/- 0.4 vs. 3.3 +/- 0.3 mEq/L (P < 0.0001). Three out of eighteen patients (16.7%) reached a final potassium level <3.0 mEq/L, and eight out of eighteen (44.5%) showed a potassium concentration decrease >20% with respect to the basal value. A mild metabolic alkalosis occurred during the procedure: pH increased from 7.35 +/- 0.02 to 7.43 +/- 0.028 (P < 0.001), and plasma bicarbonate concentration increased from 27.48 +/- 2.21 to 32.44 +/- 2.52 mmol/L (P < 0.01). Sodium and chloride did not differ in the final sample with respect to the basal sample. None of our patients experienced clinically relevant side effects related to severe electrolyte changes (i.e., >20% with respect to the basal value). Because our current therapeutic schedules include patients older than 50 years in the PBSC collection and transplantation program and since it is well known that subclinical myocardial disease may occur in up to 4% of middle-aged males, we suggest that patients aged 50 or older undergoing PBSC collection procedures be carefully monitored in order to identify significant electrolyte variation, especially if they present with low serum potassium levels. However, further investigation of larger patient series are needed to determine the clinical relevance of serum potassium changes during apheresis.
Assuntos
Eletrólitos/sangue , Neoplasias Hematológicas/sangue , Transplante de Células-Tronco Hematopoéticas , Hipopotassemia/etiologia , Flebotomia , Adolescente , Adulto , Alcalose/sangue , Alcalose/etiologia , Arritmias Cardíacas/etiologia , Arritmias Cardíacas/prevenção & controle , Criança , Eletrocardiografia , Feminino , Neoplasias Hematológicas/terapia , Humanos , Concentração de Íons de Hidrogênio , Hipocalcemia/sangue , Hipocalcemia/etiologia , Hipopotassemia/sangue , Deficiência de Magnésio/sangue , Deficiência de Magnésio/etiologia , Masculino , Pessoa de Meia-Idade , Monitorização Fisiológica , Flebotomia/efeitos adversos , Síncope/sangue , Síncope/etiologiaRESUMO
We performed HLA typing in 96 couples affected by recurrent abortion "sine causa". We matched these patients with 124 fertile couples and 204 individuals random paired. No significant difference in HLA sharing was demonstrated in the three study groups. The statistical analysis denoted significant differences in regard to HLA A3, A24, B12, and DR- comparing patients and normal members of fertile couples. The frequencies of HLA Cw5, Cw6 and DR2 were different in patients when compared with their partners.
Assuntos
Aborto Habitual/imunologia , Fertilidade , Antígenos HLA/análise , Adulto , Feminino , Antígenos HLA-A/análise , Antígenos HLA-B/análise , Antígenos HLA-C/análise , Antígenos HLA-DQ/análise , Antígenos HLA-DR/análise , Humanos , Masculino , GravidezRESUMO
Evidence for heterogeneity of several biological features of human malignant melanoma (Me) like morphology, cytogenetics, oncogenes activation, antigenic expression, metastatizing capacity and procoagulant activity are briefly reviewed in an attempt to distinguish findings related to primary vs. metastatic lesions. In our own studies monoclonal antibodies were used to study expression of MHC class I, class II products and of Me-associated antigens (MAA) on primary and metastatic Me cells. High expression of class I antigens was found in a high percentage of both primary and metastatic tumors, whereas DR and MAA showed a significant variation (from 3 to 90% of cells) in expression both in primary and in metastatic Me. When autologous cell-mediated immune responses were evaluated, it was found that Me cells from primary tumors but not those from lymph node metastases were able to stimulate autologous lymphocytes to proliferate and become cytotoxic for autologous Me. Clonal analysis of cytotoxic lymphocytes was then carried out in order to see whether the lack of lymphocytes reactivity to metastatic cells was due to the absence or to a low frequency of cytotoxic cells in the unstimulated PBL. CTL clones cytotoxic for autologous Me (Auto-Me) cells were indeed isolated. Three classes of CTL clones were identified: 1) one which is cytotoxic for Auto-Me; 2) a second one which lyse Auto-Me and allogeneic Me; and 3) a third one which is cytotoxic for Auto-Me and allogeneic normal and neoplastic cells. Metastatic Me cells, however, had the ability to suppress the stimulation of autologous PBL by alloantigens or IL-2. This effect was dose-dependent and was not due to absorption of IL-2 by Me cells. Since it has been reported that Me cells express class II MHC antigens, we investigated whether there was any correlation between autologous immune responses and DR expression on Me cells. Autologous lymphocytes stimulation was found to occur only with DR+ Me cells from primary lesions, whereas metastatic cells, either DR+ or DR-, did not stimulate autologous PBL. Moreover, the suppressive effect of metastatic Me cells was associated with their expression of DR antigens. The modulation of DR antigens on Me cells by Interferon-gamma correlated positively with their suppressive capacity. Thus, it appears that primary Me can behave differently from the metastatic one in their interactions with the immune system of autologous host. These findings suggest that DR antigens on Me cells may have an important role in the regulation of autologous immune responses.
Assuntos
Antígenos de Histocompatibilidade Classe II/imunologia , Melanoma/imunologia , Antígenos de Neoplasias , Antígenos HLA-DR , Antígenos de Histocompatibilidade Classe II/análise , Humanos , Tolerância Imunológica , Imunidade Celular , Interleucina-2/imunologia , Melanoma/secundário , Antígenos Específicos de Melanoma , Proteínas de Neoplasias/análise , Proteínas de Neoplasias/imunologia , Linfócitos T Citotóxicos/imunologiaRESUMO
The role of high dose chemo-radiotherapy with autologous bone marrow transplantation in the treatment of neoplasia remains to be clearly defined. Because of the iatrogenic morbidity, mortality and high cost of the supportive care required during the post-transplantation period of prolonged marrow aplasia, intensive therapy remains a sophisticated procedure lacking proper evaluation in clinical trials. We report here that when autologous bone marrow cells are supplemented with a small number of peripheral blood nucleated cells collected after prior myelosuppressive chemotherapy, complete hematological recovery is so prompt that myeloid toxicity appears no longer the major limiting factor of high-dose chemo-radiotherapy. The increased therapeutic index made possible by the procedure will allow us to address the issue of whether intensive cytoreductive therapy can be useful as initial treatment of selected tumors with curative intent.